Not specified in provided data

About BlueSphere Bio

BlueSphere Bio is a private, pre-revenue biotech focused on next-generation TCR-T cell therapies for oncology and rare diseases. Its core asset is the TCXpress™ platform, a high-throughput, automated TCR discovery engine designed to identify optimal TCRs against a wide array of targets, including neoantigens. The company is advancing its pipeline through early clinical trials, positioning itself in the competitive but high-potential cell therapy space. Key challenges include clinical execution, platform validation, and navigating a complex regulatory and competitive landscape.

About HMNC Brain Health

HMNC Brain Health is a disruptive, clinical-stage biopharma company leveraging an AI-powered platform to advance precision psychiatry for depression and anxiety disorders. Founded in 2010, the company is developing targeted therapies and companion diagnostics to address the high unmet medical need in Treatment-Resistant Depression, where current treatments often fail. By combining deep genomic insights with predictive analytics, HMNC aims to set new standards in personalized mental healthcare and reduce the significant societal and economic burden of these diseases.

Therapeutic Areas